Resistance of human breast-cancer cells to the pure steroidal anti- estrogen ICI 182,780 is not associated with a general loss of estrogen- receptor expression or lack of estrogen responsiveness

International Journal of Cancer

Volumn 72, Issue 6, 1997, Pages 1129-1136

  Larsen, Søren S ^a   Madsen, Mogens W ^a   Jensen, Bettina L ^a   Lykkesfeldt, Anne E ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTIESTROGEN; CATHEPSIN D; ESTROGEN RECEPTOR; FULVESTRANT; MESSENGER RNA; PROGESTERONE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER RESISTANCE; CELL GROWTH; CONTROLLED STUDY; HUMAN; HUMAN CELL; MESSENGER RNA SYNTHESIS; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR DOWN REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL NUCLEUS; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MICE; MICE, NUDE; OVARIECTOMY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0030753406     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970917)72:6<1129::AID-IJC31>3.0.CO;2-X     Document Type: Article

References (37)

1. BERRY, M., METZGER, D. and CHAMBON, P., Role of the two activating domains of the oestrogen receptor in the cell-type- and promoter-context-dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J., 9, 2811-2818 (1990).
2. BRIAND, P. and LYKKESFELDT, A.E., Effect of estrogen and anti-estrogen on the human breast-cancer cell line MCF-7 adapted to growth at low serum concentration. Cancer Res., 44, 1114-1119 (1984).
3. BRONZERT, D.A., GREENE, G.L. and LIPPMAN, M.E., Selection and characterization of a breast-cancer cell line resistant to the anti-estrogen LY 117018. Endocrinology, 117, 1409-1417 (1987).
4. BRÜNNER, N., BOYSEN, B., KIILGAARD, T.L., FRANDSEN, T.L., JIRUS, S. and CLARKE, R., Resistance to 4OH-Tamoxifen does not confer resistance to the steroidal anti-estrogen ICI 182,780, while acquired resistance to ICI 182,780 results in cross-resistance to 4OH-Tam. Breast Cancer Res. Treat., 27, 135 (1993a).
5. BRÜNNER, N., FRANDSEN, T.L., HOLST-HANSEN, C., BEI, M., THOMPSON, E.W., WAKELING, A.E., LIPPMAN, M.E. and CLARKE, R., MCF-7/LCC2: a 4-hydroxytamoxifen-resistant human breast-cancer variant that retains sensitivity to the steroidal anti-estrogen ICI 182,780. Cancer Res., 53, 3229-3232 (1993b).
6. CASTAGNETTA, L., TRAINA, A., DI CARLO, A., LATTERI, A.M., CARRUBA, G. and LEAKE, R.E., Heterogeneity of soluble and nuclear oestrogen-receptor status of involved nodes in relation to primary breast cancer. Europ. J. Cancer clin. Oncol., 23, 31-35 (1987).
7. CHO, H., NG, P.A. and KATZENELLENBOGEN, B.S., Regulation of the pS2-gene expression by estrogen in estrogen-growth-independent and -dependent MCF-7 breast-cancer cells. Brit. J. Cancer, 59, 727-738 (1991).
8. DAUVOIS, S., DANIELIAN, P.S., WHITE, R. and PARKER, M.G., Anti-estrogen ICI 164,384 reduces cellular estrogen-receptor content by increasing its turnover. Proc. nat. Acad. Sci. (Wash.), 89, 4037-4041 (1992).
9. DUMONT, J.A., BITONTI, A.J., WALLACE, C.D., BAUMANN, R.J., CASHMAN, E.A. and CROSS-DOERSEN, D.E., Progression of MCF-7 breast-cancer cells to anti-estrogen-resistant phenotype is accompanied by elevated levels of AP-1-DNA-binding activity. Cell Growth Differ., 7, 351-359 (1996).
10. FAWELL, S.E., WHITE, R., HOARE, S., SYDENHAM, M., PAGE, M. and PARKER, M.G., Inhibition of estrogen-receptor-DNA binding by the "pure" anti-estrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc. nat. Acad. Sci. (Wash.), 87, 6883-6887 (1990).
11. HERMAN, M.E. and KATZENELLENBOGEN, B.S., Response-specific anti-estrogen resistance in a newly characterized MCF-7 human breast-cancer cell line resulting from long-term exposure to transhydroxytamoxifen. J. Steroid Biochem. mol. Biol., 59, 121-134 (1996).
12. HORWITZ, K.B. and MCGUIRE, W.L., Nuclear mechanisms of estrogen action. J. biol. Chem., 253, 8185-8191 (1978).
13. HOWELL, A., DEFRIEND, D.J., ROBERTSON, J., BLAMEY, R. and WALTON, P., Response to a specific anti-oestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet, 345, 29-30 (1995).
14. HU, X.F., VERONI, M., DE LUISE, M., WAKELING, A.E., SUTHERLAND, R., WATTS, C.K.W. and ZALCBERG, J.R., Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780. Int. J. Cancer, 55, 873-876 (1993).
15. KATZENELLENBOGEN, B.S., Anti-estrogen resistance: mechanisms by which breast-cancer cells undermine the effectiveness of endocrine therapy. J. nat. Cancer Inst., 83, 1434-1435 (1991).
16. KUUKASJÄRVI, T., KONONEN, J., HELIN, H., HOLLI, K. and ISOLA, J., Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J. clin. Oncol., 14, 2584-2589 (1996).
17. LYKKESFELDT, A.E., Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer. Acta oncol., 35, Suppl. 5, 9-14 (1996).
18. LYKKESFELDT, A.E., LARSEN, S.S. and BRIAND, P., Human breast-cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int. J. Cancer, 61, 529-534 (1995).
19. LYKKESFELDT, A.E., LAURSEN, I. and BRIAND, P., Regulation of the secretion of proteins synthesized by human breast-cancer cell line MCF-7. Mol. cell. Endocrinol., 62, 287-296 (1989).
20. R-1. Cancer Res., 54, 1587-1595 (1994).
21. LYKKESFELDT, A.E. and SØRENSEN, E.K., Effect of estrogen and anti-estrogens on cell proliferation and synthesis of secreted proteins in the human breast-cancer cell line MCF-7 and a tamoxifen-resistant variant sub-line, AL-1. Acta oncol., 31, 131-138 (1992).
22. MADSEN, M.W., REITER, B.E., LARSEN, S.S., BRIAND, P. and LYKKESFELDT, A.E., Estrogen-receptor mRNA splice variants are not involved in anti-estrogen resistance in sub-lines of MCF-7 human breast-cancer cells. Cancer Res., 57, 585-589 (1997).
23. NICHOLSON, R.I., MCCLELLAND, R.A., GEE, J.M.W., MANNING, D.L., CANNON, P., ROBERTSON, J.F.R., ELLIS, I.O. and BLAMEY, R.W., Transforming growth factor-α and endocrine sensitivity in breast cancer. Cancer Res., 54, 1684-1689 (1994a).
24. NICHOLSON, R.I., MCCLELLAND, R.A., GEE, J.M.W., MANNING, D.L., CANNON, P., ROBERTSON, J.F.R., ELLIS, I.O. and BLAMEY, R.W., Epidermal-growth-factor-receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res. Treat., 29, 117-125 (1994b).
25. OSBORNE, C.K., CORONADO, E., ALLRED, D.C., WIEBE, V. and DEGREGORIO, M., Acquired tamoxifen resistance: correlation with reduced breast-tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J. nat. Cancer Inst., 83, 1477-1482 (1991).
26. OSBORNE, C.K., CORONADO-HEINSOHN, E.B., HILSENBECK, S.G., MCCUE, B.L., WAKELING, A.E., MCCLELLAND, R.A., MANNING, D.L. and NICHOLSON, R.I., Comparison of the effects of a pure steroidal anti-estrogen with those of tamoxifen in a model of human breast cancer. J. nat. Cancer Inst., 87, 746-750 (1995).
27. OSBORNE, C.K., YOCHMOWITZ, M.G., KNIGHT, W.A. III and MCGUIRE, W.L., The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer, 46, 1884-2888 (1980).
28. PINK, J.J. and JORDAN, V.C., Models of estrogen-receptor regulation by estrogens and anti-estrogens in breast-cancer cells. Cancer Res., 56, 2321-2330 (1996).
29. ROBERTSON, J.F.R., Oestrogen receptor: a stable phenotype in breast cancer. Brit. J. Cancer, 73, 5-12 (1996).
30. SACEDA, M., LIPPMAN, M.E., CHAMBON, P., LINDSEY, R.L., PONGLIKITMONGKOL, M., PUENTE, M. and MARTIN, M.B., Regulation of the estrogen receptor in MCF-7 cells by estradiol. Mol. Endocrinol., 2, 1157-1162 (1988).
31. THOMPSON, A.M., KERR, D.J. and STEEL, C.M., Transforming growth factor β1 is implicated in the failure of tamoxifen therapy in human breast cancer. Cancer, 63, 609-614 (1991).
32. VAN AGTHOVEN, T., VAN AGTHOVEN, T.L.A., DEKKER, A., FOEKENS, J.A. and DORSSERS, L.C.J., Induction of estrogen-independence of ZR-75-1 human breast-cancer cells by epigenetic alterations. Mol. Endocrinol., 8, 1474-1483 (1994).
33. VIGNON, F., CAPONY, F., CHAMBON, M., FREISS, G., GARCIA, M. and ROCHEFORT, H., Autocrine growth stimulation of the MCF 7 breast-cancer cells by the estrogen-regulated 52-K protein. Endocrinology, 118, 1537-1545 (1986).
34. WAKELING, A.E., DUKES, M. and BOWLER, J., A potent specific pure anti-estrogen with clinical potential. Cancer Res., 51, 3867-3873 (1991).
35. WESTLEY, B.R. and MAY, F.E.B., Cathepsin D and breast cancer. Europ. J. Cancer, 32A, 15-24 (1996).
36. WISEMAN, L.R., JOHNSON, M.D., WAKELING, A.E., LYKKESFELDT, A.E., MAY, F.E.B. and WESTLEY, B.R., Type-I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast-cancer cells. Europ. J. Cancer, 29A, 2256-2264 (1993).
37. WRIGHT, C., NICHOLSON, S., ANGUS, B., SAINSBURY, J.R., FARNDON, J., CAIRNS, J., HARRIS, A.L. and HORNE, C.H., Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Brit. J. Cancer, 65, 118-121 (1992).